By summer solstice, we'll know the fate of Intercept's NASH drug

Intercept Pharmaceuticals has another date with the FDA, as the regulator will decide for a second time whether to approve the biotech’s drug for patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis, or NASH.